TRANSCODE THERAPEUTICS, INC.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Partnering

Lead Candidate - TTX-MC138

Click on the animation above to see how our
​lead candidate therapeutic works
TransCode Therapeutics focuses on addressing the most significant unmet need in oncology - metastatic disease. This is when cancer spreads to other parts of the body from its origin. With no single treatment available for this type of cancer, TransCode utilizes its TTX platform in the metastatic setting with the goal to improve treatment outcomes and enable long-term survival possibilities.

Treatment Solution Specific to Metastatic Disease: TTX-MC138

Small, non-coding strands of RNA have been identified as a significant player in the pathology of cancer. One of the first miRNAs shown to have aberrant expression in cancer was miR-10b. Since the inaugural study on miR-10b, its role in cancer has been extensively validated, as a master regulator of tumor cell viability and metastasis in a range of cancers, including breast, pancreatic, ovarian, colon, glioblastomas, and others. Clinical evidence demonstrated in >700 peer-reviewed publications over the last ten years supports the link between miR-10b and metastasis across at least 18 cancer indications as well as other diseases.

​TransCode’s lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b (miR-10b) with the goal of eliminating metastasis. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others - 18 in total. ​
Picture
A small, non-coding microRNA called miRNA-10b, is shown to be the master regulator of metastasis in a range of solid tumors
Picture
Cells in the primary tumor are known to up regulate miRNA-10b which allows metastatic cells to develop, detach and migrate
Picture
Metastatic tumor cells are better equipped to safely travel to other parts of the body and develop metastases in organs different from the organ of origin
Picture
TransCode's TTX platform delivery system has the potential to treat a variety of tumor indications through effective delivery and targeting

​Pre-Clinical Results

     Metastatic Breast Cancer

In multiple pre-clinical models of triple-negative breast cancer (TNBC), treatment with low-dose chemotherapy and TTX-MC138 eliminated pre-existing local metastases in 100% of treated animals representative of stage II/III metastatic cancer. In models representative of stage IV metastatic cancer, treatment with low-dose chemotherapy and TTX-MC138 resulted in elimination of distant metastases in 65% of animals treated.
​Notably, no recurrence of metastases occurred following TTX-MC138 treatment cessation. 

Picture
Picture
Picture
Sources: Yoo B, et al. Cancer Res. 2015;75(20):4407-4415; Yoo B, et al. Sci Rep. 2017;7:45060; Figure 11 in S-1 Preclinical results of TTX-MC138 in models of metastatic breast cancer.

    Pancreatic Cancer

Positive preclinical results achieved with its lead candidate therapeutic, TTX-MC138, in pancreatic adenocarcinoma. 
​
TTX-MC138, applied as monotherapy, in a murine model of pancreatic adenocarcinoma, showed that forty percent (40%) of animals treated had complete responses, defined as complete regression of disease and long-term survival without recurrence.
Survival
Picture
  • Results: 40% of animals treated with TTX-MC138 showed 100% regression of disease without recurrence during the length of the study (20wks)
miR-10b Inhibiton
Picture
  • qRT-PCR shows target engagement and the potential to use​ miR-10b expression in serum as a  biomarker of therapeutic success
Picture

Clinical Path Forward

A first in human Phase O study with TTX-MC138 is planned for 3Q of 2023, and is expected to be followed by Phase I/II.

More About TTX-MC138

​For additional information about our groundbreaking lead investigational candidate, TTX-MC138, see the information sheet below.
Picture
Download

Other Candidates

Learn more about TransCode's other therapeutic candidates.
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

Mission
clinical trials
careers

​

About

​METASTATIC DISEASE
TTX-MC138
​SCIENCE
​PIPELINE
​DELIVERY PLATFORM
​OTHER PRODUCTS
​LEADERSHIP


Publications

​PUBLICATIONS

Partnering

partnering

Contact/Support

CONTACT
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2025.​ ALL RIGHTS RESERVED.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Partnering